Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative fluoropyrimidine and oxaliplatin with or without panitumumab in high-risk operable colon cancer
ISRCTN87163246Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin and panitumumab in colon cancer (3 arms), sponsored by University of Birmingham. Primary endpoints: Freedom from recurrent or persistent disease within 2 years and Pathological downstaging. Started Apr 2008; status: completed.
02
Drugs
oxaliplatinpanitumumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on ISRCTN87163246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87163246.